Source: Deming P. Viral hepatitis. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach. 10th ed. New York, NY: McGraw-Hill; 2017. http://accesspharmacy.mhmedical.com/content.aspx?bookid=1861§ionid=132516044. Accessed April 10, 2017.
Used when pre- or postexposure prophylaxis against HAV infection needed in persons for whom vaccination not an option.
Preferred for persons >40 years old, children <12 months, immunocompromised persons, and persons with chronic liver disease3
Most effective within 2 weeks after exposure1
May be given with HAV vaccine, but at different sites1
TABLE 1.Recommendations for Hepatitis A Vaccination ||Download (.pdf) TABLE 1. Recommendations for Hepatitis A Vaccination
|All children at 1 year of age |
|Children and adolescents ages 2–18 years who live in states or communities where routine hepatitis A vaccination has been implemented because of high disease incidence |
|Persons traveling to or working in countries that have high or intermediate endemicity of infectiona |
|Men who have sex with men |
|Illegal-drug users |
|Persons who have occupational risk for infection (eg, persons who work with HAV-infected primates or HAV in a research laboratory setting) |
|Persons who have clotting factor disorders |
|Persons who have chronic liver disease (eg, persons with chronic liver disease caused by hepatitis B or C and persons awaiting liver transplants) |
TABLE 2.Recommended Dosing of Havrix and Vaqtaa 4,5